Importantly, TNKSi has been reported to inhibit key cancer-promoting signaling pathways (Sanchez-Vega et al., 2018), such as the wingless-type mammary tumor virus integration site (WNT)/β-catenin pathway (Huang et al., 2009), the yes-associated protein 1 (YAP) pathway (Wang et al., 2015), the PI3K/AKT serine/threonine kinase 1 (AKT) pathway (Li et al., 2015), and the notch receptor (NOTCH) pathway (Bhardwaj et al., 2017). The gene discussed is AKT1; the disease is cancer.